1. Scrip
  2. >>Business
  3. >>Earnings

Dr Reddy’s Charts Sharp Cost Overhaul Amid Weak Q1

 
• By Anju Ghangurde

Dr Reddy’s plans a significant review of its “cost structure”, including potential portfolio rationalization and R&D site optimization, as part of broader efforts to emerge “leaner and agile” as it grapples with multiple business challenges that saw it post disappointing first quarter earnings.

Pharma pills

Dr. Reddy's Laboratories Ltd. reported a weak first quarter but the management hopes that sustained efforts in three “high priority” areas including setting right a skewed cost structure and strengthening manufacturing and quality compliance could restore momentum.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business